A pilot study of BW A515U (6-deoxyacyclovir) in chronic hepatitis B virus infection

I. V D Weller; R. S. Tedder; P. Karayiannis; H. C. Thomas; A. P. Fiddian

doi:10.1016/S0168-8278(86)80109-X

A pilot study of BW A515U (6-deoxyacyclovir) in chronic hepatitis B virus infection

I. V D Weller, R. S. Tedder, P. Karayiannis, H. C. Thomas, A. P. Fiddian

Medical School

Research output: Contribution to journal › Article › peer-review

Abstract

BW A515U (6-Deoxyacyclovir) is a pro-drug of acyclovir and almost 100% is absorbed orally. 250 mg orally 6-hourly for 10 days was given to 4 hepatitis B surface antigen/e antigen-positive carriers. No consistent effect on productive viral replication, as determined by serum DNA polymerase and DNA levels was observed. The changes that occurred in these markers and transaminases in 1 patient were attributed to a spontaneous depression of productive viral replication.

Original language	English
Journal	Journal of Hepatology
Volume	3
Issue number	SUPPL. 2
DOIs	https://doi.org/10.1016/S0168-8278(86)80109-X
Publication status	Published - 1986

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0168-8278(86)80109-X

Cite this

@article{97501621ba684cb0afb54e0acc812c80,

title = "A pilot study of BW A515U (6-deoxyacyclovir) in chronic hepatitis B virus infection",

abstract = "BW A515U (6-Deoxyacyclovir) is a pro-drug of acyclovir and almost 100% is absorbed orally. 250 mg orally 6-hourly for 10 days was given to 4 hepatitis B surface antigen/e antigen-positive carriers. No consistent effect on productive viral replication, as determined by serum DNA polymerase and DNA levels was observed. The changes that occurred in these markers and transaminases in 1 patient were attributed to a spontaneous depression of productive viral replication.",

author = "Weller, {I. V D} and Tedder, {R. S.} and P. Karayiannis and Thomas, {H. C.} and Fiddian, {A. P.}",

year = "1986",

doi = "10.1016/S0168-8278(86)80109-X",

language = "English",

volume = "3",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

number = "SUPPL. 2",

}

TY - JOUR

T1 - A pilot study of BW A515U (6-deoxyacyclovir) in chronic hepatitis B virus infection

AU - Weller, I. V D

AU - Tedder, R. S.

AU - Karayiannis, P.

AU - Thomas, H. C.

AU - Fiddian, A. P.

PY - 1986

Y1 - 1986

N2 - BW A515U (6-Deoxyacyclovir) is a pro-drug of acyclovir and almost 100% is absorbed orally. 250 mg orally 6-hourly for 10 days was given to 4 hepatitis B surface antigen/e antigen-positive carriers. No consistent effect on productive viral replication, as determined by serum DNA polymerase and DNA levels was observed. The changes that occurred in these markers and transaminases in 1 patient were attributed to a spontaneous depression of productive viral replication.

AB - BW A515U (6-Deoxyacyclovir) is a pro-drug of acyclovir and almost 100% is absorbed orally. 250 mg orally 6-hourly for 10 days was given to 4 hepatitis B surface antigen/e antigen-positive carriers. No consistent effect on productive viral replication, as determined by serum DNA polymerase and DNA levels was observed. The changes that occurred in these markers and transaminases in 1 patient were attributed to a spontaneous depression of productive viral replication.

UR - http://www.scopus.com/inward/record.url?scp=0023026476&partnerID=8YFLogxK

U2 - 10.1016/S0168-8278(86)80109-X

DO - 10.1016/S0168-8278(86)80109-X

M3 - Article

C2 - 3598153

AN - SCOPUS:0023026476

SN - 0168-8278

VL - 3

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - SUPPL. 2

ER -

A pilot study of BW A515U (6-deoxyacyclovir) in chronic hepatitis B virus infection

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this